Eledon Pharmaceuticals (ELDN) Stock Forecast & Price Target

Eledon Pharmaceuticals Inc. exhibits a promising outlook primarily due to the encouraging results of its lead compound, tegoprubart, which demonstrated the potential to improve graft survival and kidney function in transplant patients compared to the standard of care, tacrolimus. The drug's performance in terms of estimated glomerular filtration rate (eGFR), stabilizing at approximately 68 mL/min/1.73m² through 12 months, suggests a noteworthy improvement over historical data that reported eGFRs of approximately 53 mL/min/1.73m² with traditional therapies. Furthermore, tegoprubart's favorable safety and tolerability profile, indicating reduced metabolic, neurologic, and cardiovascular toxicities, positions the company to capitalize on significant therapeutic advancements in the transplantation and autoimmune disease sectors.

Eledon Pharmaceuticals reported a net loss of $17.5 million for the third quarter of 2025, a stark decline from the $77 million net income reported in the same period the previous year, which was bolstered by a substantial non-cash gain. The company faces significant challenges, including the potential failure of its primary compound, tegoprubart, in clinical trials, as well as risks associated with regulatory approval and market penetration, which could hinder future sales. Additionally, concerns about obtaining reasonable reimbursement and competition may further diminish the commercial viability of their drug, raising important financial risks for investors.